OPEN ACCESS Freely available online

ISSN: 2327-5073
Clinical Microbiology:
Open Access

Commentary

Tracking Antimicrobial Susceptibility in *Escherichia coli*

Leal Elena*

Department of Clinical Microbiology, University of Calgary, Calgary, Canada

DESCRIPTION

Escherichia coli (*E. coli*) is a commonly encountered bacterium that can inhabit the intestines of humans and animals. While most strains of *E. coli* are harmless, some can cause infections, ranging from urinary tract infections to severe bloodstream infections. The emergence of antimicrobial resistance among *E. coli* strains poses a significant challenge to public health globally. This article aims to explore the antimicrobial susceptibility figures among *E. coli*, shedding light on the current landscape of resistance and the implications for clinical management. Antimicrobial resistance refers to the ability of bacteria to survive and grow in the presence of antimicrobial agents that were once effective in treating infections. *E. coli* has demonstrated a remarkable capacity to acquire resistance genes through various mechanisms such as mutation and horizontal gene transfer. This has resulted in strains of *E. coli* that are resistant to multiple antibiotics, limiting treatment options and increasing the risk of treatment failure. Antimicrobial susceptibility testing plays a crucial role in guiding appropriate antibiotic therapy. It involves determining the susceptibility or resistance of bacterial isolates to specific antimicrobial agents. The results of these tests are typically reported as Minimum Inhibitory Concentration (MIC) values or as categorical interpretations based on established breakpoints.

E. coli susceptibility testing covers a wide range of antimicrobial agents. This class includes penicillins, cephalosporins, and carbapenems. Resistance to beta-lactams in *E. coli* is often mediated by the production of beta-lactamase enzymes or changes in the bacterial penicillin-binding proteins. Fluoroquinolones are synthetic antibiotics that target bacterial DNA gyrase and topoisomerase IV. However, resistance to these agents has been increasing, primarily due to mutations in the target genes. Aminoglycosides are broad-spectrum antibiotics that inhibit bacterial protein synthesis. Resistance to aminoglycosides in *E. coli* can occur through enzymatic inactivation or reduced uptake of the drug. This combination antibiotic inhibits sequential steps in the bacterial folic acid synthesis pathway. *E. coli* resistance to TMP-SMX is commonly mediated by the acquisition of genes encoding dihydrofolate reductase enzymes with reduced affinity for the drug.

Tetracyclines interfere with bacterial protein synthesis by binding to the bacterial ribosome. Resistance to tetracyclines can occur through efflux pumps or ribosomal protection mechanisms.

The antimicrobial susceptibility figures among *E. coli* vary geographically and over time. Extended- ESBL-producing *E. coli* strains have become increasingly prevalent. ESBLs are enzymes capable of hydrolyzing extended-spectrum cephalosporins and monobactams, leading to resistance. Carbapenem-Resistant *E. coli* (CRE) strains, often associated with the production of carbapenemases, have emerged as a serious global health threat. Carbapenems are considered last-resort antibiotics for the treatment of multidrug-resistant infections. *E. coli* resistance to fluoroquinolones has been on the rise, limiting the effectiveness of this class of antibiotics. This resistance is often associated with chromosomal mutations in the genes encoding DNA gyrase and topoisomerase IV.

E. coli strains resistant to multiple antimicrobial classes, including beta-lactams, fluoroquinolones, and aminoglycosides, have been identified. Co-resistance complicates treatment options and necessitates the use of alternative and potentially more toxic antibiotics.

The increasing prevalence of antimicrobial resistance among *E. coli* strains poses significant challenges for clinicians. It limits the choice of antibiotics, prolongs hospital stays, increases healthcare costs, and can lead to treatment failures and adverse patient outcomes. To combat this problem, it is crucial to promote prudent antimicrobial use, implement infection prevention measures, and encourage the development of novel treatment strategies. Antimicrobial resistance among *E. coli* strains is a pressing global concern. Understanding the antimicrobial susceptibility figures is essential for guiding appropriate antibiotic therapy and preventing treatment failures. The emergence of resistance to multiple antibiotic classes underscores the urgent need for a comprehensive and multifaceted approach to combat antimicrobial resistance. Continued surveillance, rational use of antibiotics, and the development of novel therapeutic options are crucial for managing *E. coli* infections effectively and safeguarding public health.

Correspondence to: Leal Elena, Department of Clinical Microbiology, University of Calgary, Calgary, Canada, E-mail: Lealelena@gamil.com

Received: 29-May-2023, Manuscript No. CMO-23-21943; **Editor assigned:** 01-Jun-2023, Pre QC No. CMO-23-21943(PQ); **Reviewed:** 16-Jun-2023, QC No. CMO-23-21943; **Revised:** 22-Jun-2023, Manuscript No. CMO-23-21943(R); **Published:** 30-Jun-2023, DOI: 10.35248/2327-5073.23.12.346.

Citation: Elena L (2023) Tracking Antimicrobial Susceptibility in *Escherichia coli*. Clin Microbiol. 12:346.